The Unfold artificial intelligence platform from US-based Avenda Health, which creates a cancer probability map based on patient-specific data from prostate biopsies and imaging. It has been given a category III Current Procedural Terminology (CPT) code.
Temporary Category III codes are used to report on new and experimental services and procedures. They also enable the AMA to gather and assess usage data for the device.
The device is described as a non-invasive prostate cancer estimation map in the new CPT code. This will be released with the January 2024 set. It is created through augmentative analysis of image-guided fusion biopsy and pathology data.
“This recognition by the CPT Editorial Panel is a testament to our dedication to providing cutting-edge solutions in the field of cancer diagnosis and treatment,” said Brittany Berry-Pusey, co-founder of Avenda.
“The new CPT code solidifies our position as a frontrunner in revolutionizing cancer care and our commitment to making our technology accessible to all patients.”
Together with Avenda’s FocalPoint System, which is the third product of the company meant for use in the indication but has not yet received approval. Unfold AI is currently a part of one US-centered interventional clinical trial (NCT06047509).
According to the Pharmaceutical Intelligence Centre at GlobalData, the prostate cancer market in North America is expected to reach a valuation of approximately $12.6 billion by 2027. According to estimates from the American Cancer Society, there have been about 34,700 deaths and 288,300 new cases of prostate cancer so far in 2023.
It follows Avenda’s announcement that it has teamed with Urology Associates. A clinic in Maryland, that assesses the Unfold AI device in procedures. This is with the intention of bringing it to more teaching hospitals in the US.
Recently, Quilbim, a Spanish software provider, partnered with Philips to introduce an AI-powered device. It checks for prostate cancer through imaging and reporting solutions.
The advancements in MedTech are on the rise. Specifically in targeting cancerous cells.
The fact that medical research and advancements are geared toward men is a great topic. Regardless of the technological aspect of it. Whether we like it or not, these factors do not give enough attention to men. One crucial point is that technological advancements are giving equal priority to men’s health and women’s.
Inside Telecom provides you with an extensive list of content covering all aspects of the Tech industry. Keep an eye on our Medtech section to stay informed and updated with our daily articles.